246 related articles for article (PubMed ID: 34129693)
1. Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.
van Dalem J; Driessen JHM; Burden AM; Stehouwer CDA; Klungel OH; de Vries F; Brouwers MCGJ
Hepatology; 2021 Nov; 74(5):2467-2477. PubMed ID: 34129693
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.
Krishnan A; Schneider CV; Hadi Y; Mukherjee D; AlShehri B; Alqahtani SA
Diabetologia; 2024 Mar; 67(3):483-493. PubMed ID: 38117293
[TBL] [Abstract][Full Text] [Related]
3. Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
Engström A; Wintzell V; Melbye M; Svanström H; Eliasson B; Gudbjörnsdottir S; Hveem K; Jonasson C; Hviid A; Ueda P; Pasternak B
Hepatology; 2024 Jun; 79(6):1401-1411. PubMed ID: 38085855
[TBL] [Abstract][Full Text] [Related]
4. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
[TBL] [Abstract][Full Text] [Related]
5. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B
Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis.
Ding C; Tang Y; Zhu W; Huang P; Lian P; Ran J; Huang X
Acta Diabetol; 2022 Apr; 59(4):519-533. PubMed ID: 34988690
[TBL] [Abstract][Full Text] [Related]
7. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
8. Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis.
Park MJ; Kim H; Kim MG; Kim K
Clin Mol Hepatol; 2023 Jul; 29(3):693-704. PubMed ID: 36907574
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
Pradhan R; Yin H; Yu O; Azoulay L
Diabetes Care; 2022 Apr; 45(4):819-829. PubMed ID: 35104330
[TBL] [Abstract][Full Text] [Related]
10. Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors.
Htoo PT; Buse JB; Gokhale M; Marquis MA; Pate V; Stürmer T
Eur J Clin Pharmacol; 2016 Aug; 72(8):1013-23. PubMed ID: 27165664
[TBL] [Abstract][Full Text] [Related]
11. Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists.
Gracen L; Muthukumara W; Aikebuse M; Russell A; O'Beirne J; Irvine KM; Williams S; Puri G; Valery PC; Hayward KL; Powell EE
Ann Hepatol; 2023; 28(6):101142. PubMed ID: 37468097
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease.
Jang H; Kim Y; Lee DH; Joo SK; Koo BK; Lim S; Lee W; Kim W
JAMA Intern Med; 2024 Apr; 184(4):375-383. PubMed ID: 38345802
[TBL] [Abstract][Full Text] [Related]
13. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
14. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Yang CT; Yang CY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
[TBL] [Abstract][Full Text] [Related]
15. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.
Yang JY; Moon AM; Kim H; Pate V; Barritt AS; Crowley MJ; Buse JB; Stürmer T; Alexopoulos AS
J Diabetes Complications; 2020 Nov; 34(11):107706. PubMed ID: 32843283
[TBL] [Abstract][Full Text] [Related]
16. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
Patel Chavez C; Cusi K; Kadiyala S
J Clin Endocrinol Metab; 2022 Jan; 107(1):29-38. PubMed ID: 34406410
[TBL] [Abstract][Full Text] [Related]
17. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 receptor agonists in NAFLD.
Petit JM; Vergès B
Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Dougherty JA; Guirguis E; Thornby KA
Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]